v3.26.1
Segments
 6 Months Ended
Jun. 30, 2026
Segments [Abstract]  
SEGMENTS

NOTE 9 - SEGMENTS

 

Operating Segments

 

Management assessed the Company’s operating and reportable segments in accordance with ASC 280, Segment Reporting. The Company’s CEO is the chief operating decision maker (“CODM”).

 

Following the acquisition of Scinai Biopharma Services Ltd, The company identified one reportable segment, the CDMO operation.

 

The CDMO is being operated from two facilities, located in Jerusalem and Yavne, Israel, which have complementary technical and operational capabilities, the company manages and assess performance of both facilities on an integrated basis and utilize common management and operational resources. The Company also continues to conduct proprietary research and development activities which are presented as others.

 

The following table presents the significant expense categories and other segment items regularly reviewed by the CODM in assessing performance and allocating resources.

 

    Six months ended June 30, 2026  
    CDMO     Other     Total  
                   
Revenues                
External     949       -       949  
Total   $ 949     $ -     $ 949  
                         
Cost of revenues                        
External     (3,319 )             (3,319 )
Total   $ (3,319 )   $ -     $ (3,319 )
                         
Research and development expenses, net                        
External     -       (839 )     (839 )
Total     -     $ (839 )   $ (839 )
                         
Segment operational loss     (3,774 )     (839 )     (4,613 )
Gain from bargain purchase     6,401       -       6,401  
Financial expenses (income), net     (214 )     -       (214 )
Net profit (loss)   $ 2,413     $ (839 )   $ 1,574  

 

    Six months ended June 30, 2025  
    CDMO     Other     Total  
                   
Revenues                      
External     773       -       773  
Total   $ 773     $ -     $ 773
                         
Cost of revenues     (2,043 )     -       (2,043 )
External     -       -       -  
Total   $ (2,043 )   $ -     $ (2,043 )
                         
Research and development expenses, net             -          
External     -       (1,237 )     (1,237 )
Total   $ -     $ (1,237 )   $ (1,237 )
                         
Segment operational loss     (2,526 )     (1,237 )     (3,763 )
Financial expenses (income), net     (371 )     -       (371 )
Net loss   $ (2,897 )   $ (1,237 )   $ (4,134 )